Loading institutional data...
Loading institutional data...
Held by 174 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$126M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -189%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M 100.0% | $83.3M 100.0% | $90.2M 100.0% | $112.7M 100.0% | $470.3M 100.0% | $154.6M 100.0% | $35.2M 100.0% | $218.5M 100.0% | $10.4M 100.0% | $4.6M 100.0% |
| Cost of Revenue | — | $33.6M 40.3% | $37.2M 41.2% | $54.5M 48.4% | $51.8M 11.0% | $35.7M 23.1% | $8.2M 23.4% | $9.6M 4.4% | $1.7M 16.4% | $98K 2.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $6K 0.1% | $98K 2.1% |
| Research & Development | $228.3M 133.9% | $208.5M 250.2% | $232.3M 257.4% | $242.5M 215.1% | $181.4M 38.6% | $166.3M 107.6% | $124.2M 352.5% | $83.9M 38.4% | $57.2M 550.6% | $45.5M 991.1% |
| Selling, General & Admin | $82.9M 48.6% | $76.6M 91.9% | $88.5M 98.1% | $85.3M 75.7% | $79.3M 16.9% | $63.8M 41.3% | $51.8M 147.1% | $36.9M 16.9% | $27.2M 262.0% | $23.6M 514.1% |
| Total Operating Expenses | $331.6M 194.6% | $316.7M 380.0% | $358.4M 397.1% | $375.6M 333.2% | $310.4M 66.0% | $273.8M 177.1% | $184.2M 522.9% | $130.4M 59.7% | $86.3M 830.2% | $69.9M 1523.8% |
| Operating Income | -$161.2M -94.6% | -$233.3M -280.0% | -$268.1M -297.1% | -$262.9M -233.2% | $160.0M 34.0% | -$119.2M -77.1% | -$149.0M -422.9% | $88.1M 40.3% | -$75.9M -730.2% | -$65.3M -1423.8% |
| Interest Expense | $45.0M 26.4% | $12.7M 15.2% | $6.9M 7.6% | $23.3M 20.6% | $26.3M 5.6% | $771K 0.5% | — | — | — | — |
| Interest & Investment Income | $12.2M 7.2% | $12.1M 14.5% | $9.1M 10.1% | $5.5M 4.9% | — | — | — | — | — | — |
| Other Income (Expense), net | -$32.7M -19.2% | $6.2M 7.5% | $4.5M 5.0% | -$17.5M -15.6% | -$18.7M -4.0% | $13.2M 8.6% | $51.5M 146.2% | $16.0M 7.3% | $2.7M 26.1% | $1.9M 42.2% |
| Pretax Income | -$193.9M -113.8% | -$227.1M -272.5% | -$263.6M -292.2% | -$280.4M -248.8% | $141.2M 30.0% | -$106.0M -68.6% | -$97.5M -276.7% | $104.1M 47.6% | -$73.2M -704.0% | -$63.4M -1381.6% |
| Income Tax Expense | $0 0.0% | $0 0.0% | -$152K -0.2% | -$84K -0.1% | $13.4M 2.9% | $5.2M 3.4% | -$2.8M -7.8% | $4.2M 1.9% | $0 0.0% | -$435K -9.5% |
| Net Income | -$193.9M -113.8% | -$227.1M -272.5% | -$263.5M -292.0% | -$280.3M -248.7% | $127.8M 27.2% | -$111.3M -72.0% | -$94.7M -268.9% | $99.9M 45.7% | -$73.2M -704.0% | -$63.0M -1372.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $3.01 | $-2.98 | $-2.58 | $2.99 | $-2.45 | $-2.38 |
| EPS (Diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| Weighted Avg Shares (Basic) | 51.6M | 49.5M | 43.7M | 43.2M | 42.4M | 37.3M | 36.7M | 33.4M | 29.9M | 26.4M |
| Weighted Avg Shares (Diluted) | 51.6M | 49.5M | 43.7M | 43.2M | 43.9M | 37.3M | 36.7M | 36.6M | 29.9M | 26.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
Where each multiple sits in its own 11-yr range · 36th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 4.4 | 23.4 | 23.1 | 11.0 | 48.4 | 41.2 | 40.3 | — |
| R&D | 38.4 | 352.5 | 107.6 | 38.6 | 215.1 | 257.4 | 250.2 | 133.9 |
| SG&A | 16.9 | 147.1 | 41.3 | 16.9 | 75.7 | 98.1 | 91.9 | 48.6 |
| Operating Income | 40.3 | -422.9 | -77.1 | 34.0 | -233.2 | -297.1 | -280.0 | -94.6 |
| Income Tax | 1.9 | -7.8 | 3.4 | 2.9 | -0.1 | -0.2 | 0.0 | 0.0 |
| Net Income | 45.7 | -268.9 | -72.0 | 27.2 | -248.7 | -292.0 | -272.5 | -113.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RGNX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| RGNX | $406M | — | — | 2.4× | 105% | — | -114% | -189% | -189% | — | 174 |
Peers = companies sharing RGNX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.